Back to Search
Start Over
Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis.
- Source :
-
Iranian Journal of Pharmaceutical Research . 2014, Vol. 13 Issue 4, p1357-1367. 11p. - Publication Year :
- 2014
-
Abstract
- Toxicity and drug resistance against pentavalent antimonials, medications of choice in treatment of leishmaniasis for more than 5 decades, have become important subjects globally. This study was a randomized, open labeled trial that was designed to determine efficacy and safety of IMOD as a novel herbal immunomodulator drug for treatment of canine visceral leishmaniasis (CVL). Twenty healthy mongrel dogs were infected with Iranian strain of L. Infantum amastigotes and randomly divided to 5 groups with four animals for each included on: I: negative control (non-infected) II: Glucantime® III: Glucantime® plus IMOD (immune-chemotherapy) IV: IMOD and V: positive control (non-treated). Physical examination, hematological, biochemical, serological, parasitological, pathological and imaging evaluations were performed pre-/postinterventions every month for 3 months. Comparing with control groups (I&V), immune-chemotherapy group (Glucantime® plus IMOD) showed significantly higher efficacy in resolving the clinical signs and hematobiochemistry factors. Based on our results, using IMOD in combination with meglumine antimoniate (Glucantime®) has significantly improved CVL than the latter drug alone. So, it seems this new herbal medicine is useful as adjuvant therapy for canine visceral leishmaniasis. [ABSTRACT FROM AUTHOR]
- Subjects :
- *LEISHMANIA mexicana
*LEISHMANIA
*PSYCHODIAGNOSTICS
*ADJUVANT treatment of cancer
Subjects
Details
- Language :
- English
- ISSN :
- 17350328
- Volume :
- 13
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Iranian Journal of Pharmaceutical Research
- Publication Type :
- Academic Journal
- Accession number :
- 98538110